Table 1.
Baseline variables | Early EST (n=230) | Deferred EST (n=443 ) | Significance (p value) |
---|---|---|---|
Mean age (years) | 56 ± 10 | 56 ± 11 | 0.92 |
Male gender (%) | 83 | 88 | 0.06 |
Body mass index | 28 ± 4.3 | 28 ± 4.5 | 0.33 |
Diabetes (%) | 19 | 22 | 0.16 |
Smoking (%) | 41 | 43 | 0.30 |
Beta blocker (%) | 78 | 75 | 0.27 |
Abciximab (%) | 65 | 77 | <0.01 |
Multivessel disease (%) | 53 | 47 | 0.10 |
>1 vessel stented (%) | 2.6 | 7.4 | <0.01 |
>1 stent used (%) | 26 | 31 | 0.09 |
Total stent length per patient (mm) | 22 ± 10 | 25 ± 14 | 0.05 |
Mean stent diameter (mm) | 3.1 ± 0.9 | 3.1 ± 0.6 | 0.67 |
Drug eluting stents (%) | 10 | 35 | <0.01 |
LVEF (%) | 49 ± 11 | 50 ± 11 | 0.06 |
Time to EST (days) | 4.9 ± 1.4 | 21.4 ± 14.6 | <0.01 |
% of PredMax HR achieved | 84 ± 11 | 84 ± 13 | 0.93 |
METS achieved | 8.1 ± 2.3 | 8.3 ± 2.7 | 0.79 |
Positive test (%) | 12.2 | 5.6 | <0.01 |
LVEF, left ventricular ejection fraction; mm, millimetres; b.p.m, beats per minute; PredMax, Predicted Maximum; HR, heart rate